OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Jennifer Pritzker Sells 16,300 Shares of Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) major shareholder Jennifer Pritzker sold 16,300 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $24.74, for a total transaction of $403,262.00. Following the completion of the transaction, the insider directly owned 6,881,464 shares in the company, valued at approximately $170,247,419.36. The trade was a 0.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

OrthoPediatrics Stock Down 1.9%

Shares of KIDS stock opened at $24.03 on Thursday. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. OrthoPediatrics Corp. has a 12 month low of $14.42 and a 12 month high of $26.74. The stock has a market cap of $627.42 million, a P/E ratio of -14.30 and a beta of 0.98. The company has a 50 day simple moving average of $21.23 and a two-hundred day simple moving average of $18.58.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. The firm had revenue of $70.51 million during the quarter, compared to the consensus estimate of $68.21 million. On average, research analysts expect that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year.

Institutional Trading of OrthoPediatrics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in OrthoPediatrics in the 2nd quarter worth $24,347,000. Millennium Management LLC boosted its holdings in shares of OrthoPediatrics by 48.0% during the 4th quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock valued at $24,802,000 after purchasing an additional 452,840 shares during the last quarter. AIGH Capital Management LLC purchased a new position in shares of OrthoPediatrics during the second quarter valued at about $5,161,000. Nantahala Capital Management LLC purchased a new position in shares of OrthoPediatrics during the second quarter valued at about $4,636,002,000. Finally, AWM Investment Company Inc. bought a new stake in shares of OrthoPediatrics in the second quarter worth about $4,537,000. 69.05% of the stock is currently owned by institutional investors.

Trending Headlines about OrthoPediatrics

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: OrthoPediatrics completed the full U.S. commercial launch of its 3P™ Pediatric Plating Platform® Hip System after more than 350 successful implantations during a limited release. The company said the system addresses pediatric hip trauma and deformities, improves fixation and surgical workflow, and is the first of several planned systems in a broader plating portfolio. The launch provides a potential long-term revenue and market-share opportunity, although the company did not provide specific financial guidance. OrthoPediatrics Announces Full Commercial Launch of 3P Pediatric Plating Platform Hip System
• Neutral Sentiment: Reported short interest was listed as zero shares with a zero-day short-interest ratio. However, the filing data also showed an invalid “NaN” change, making the statistic unreliable and providing little usable insight into potential short-selling pressure.
• Negative Sentiment: Director David R. Pelizzon and major shareholder entities associated with Squadron Capital and Jennifer N. Pritzker reported sales totaling 38,300 shares for approximately $943,302 across August 24–26, at prices ranging from $24.28 to $25.75. The transactions reduced the reported position by only about 0.56%, leaving ownership of roughly 6.86 million shares, so the sales appear relatively small compared with the remaining stake. Nevertheless, repeated insider selling can weigh on sentiment, particularly with KIDS trading near its 52-week high. SEC insider transaction filing

Wall Street Analysts Forecast Growth

KIDS has been the topic of several analyst reports. Piper Sandler reaffirmed an “overweight” rating and set a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Truist Financial set a $22.00 target price on shares of OrthoPediatrics in a report on Wednesday, August 5th. TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Finally, Needham & Company LLC raised their price target on OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, OrthoPediatrics has an average rating of “Moderate Buy” and a consensus price target of $26.44.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.